骨髓纤维化患者接受αβTCR与CD19去除干细胞移植时围移植期使用ruxolitinib的研究
Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantation
荷兰乌得勒支大学医学中心团队在Bone Marrow Transplantation发表研究,聚焦骨髓纤维化患者在接受αβTCR与CD19去除异基因造血干细胞移植期间使用ruxolitinib。
Data availability
The data that support the findings of this study are available from the EBMT registry, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the corresponding author.
References
McLornan D, Eikema DJ, Czerw T, Kroger N, Koster L, Reinhardt HC, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transpl. 2021;56:2160–72.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10.
Kroger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, et al. Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:2152–6.
Hobbs GS, Haesook TK, Hao R, Schroeder MA, Tamari R, Wall S, et al. Phase II study of peri- and post-transplant ruxolitinib for patients with myelofibrosis receiving allogeneic hematopoietic cell transplantation. JCO Oncol Adv. 2025;2:1–10.
Stuut AHG, Nijssen C, van der Wagen L, van Rhenen A, Daenen LGM, Janssen A, et al. Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT. Bone Marrow Transplant. 2025;60:673–81.
Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36:856–64.
Chiusolo P, Bacigalupo A, Salit R, Schroeder T, Finazzi MC, Gurnari C, et al. PTCy or ATG for Matched Transplantation in Myelofibrosis. Am J Hematol. 2026;101:1192–5.
Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024;59:550–7.
Salit RB, Hexner EO, Gagelmann N, Kroger N, McLornan DP, Jain T, et al. Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus. Leukemia. 2025;39:2862–5.
Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, et al. Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation. Hemasphere. 2023;7:e921.
Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Luck C, et al. Clearance of driver mutations after transplantation for myelofibrosis. N Engl J Med. 2025;392:150–60.
Funding
Dutch Cancer Society (KWF; #13493) to MdW, Leukemiefonds to MdW.
Author information
Author notes
These authors contributed equally: Anniek Stuut, Flores Weverling.
These authors jointly supervised this work: Jurgen Kuball, Moniek de Witte.
Authors and Affiliations
Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Anniek Stuut, Flores Weverling, Julia Drylewicz, Jurgen Kuball & Moniek de Witte
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
Flores Weverling, Anke Janssen, Frances Verheij, Iris Brinkman, Klaartje Nijssen, Pleun Schonewille, Christien Oudbier, Anna van Rhenen, Lotte van der Wagen, Laura Daenen, Reinier Raymakers, Jurgen Kuball & Moniek de Witte
Cell Therapy Facility, University Medical Center Utrecht, Utrecht, The Netherlands
Kasper Westinga
Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands
Tim Hutten & Lisette van de Corput
Authors
- Anniek Stuut
- Flores Weverling
- Anke Janssen
- Frances Verheij
- Iris Brinkman
- Klaartje Nijssen
- Pleun Schonewille
- Christien Oudbier
- Anna van Rhenen
- Lotte van der Wagen
- Laura Daenen
- Reinier Raymakers
- Kasper Westinga
- Tim Hutten
- Lisette van de Corput
- Julia Drylewicz
- Jurgen Kuball
- Moniek de Witte
Contributions
MdW was responsible for the conception and design of the study. MdW and JK were responsible for funding acquisition. AS, FW, JD, JK, and MdW contributed to data analysis and interpretation. AS, FW, JK, and MdW were responsible for writing the manuscript and preparing the figures. AS and FW had full access to and verified the underlying data. AJ, CO, AvR, LvdW, LD, RR, JK, and MdW were responsible for resource provision (patients). AS, FW, and MdW were responsible for manuscript submission. AS, FW, FV, IB, KN, PS, KW, TH, and LvdC were responsible for the collection and assembly of data. All authors critically revised the manuscript and approved the final version.
Corresponding author
Correspondence to Moniek de Witte.
Ethics declarations
Competing interests
JK is inventor on multiple patents dealing with gdTCRs, ligands, isolation strategies of engineered immune cells. JK is cofounder and shareholder of Gadeta (www.gadeta.nl). JK received research, advisor and clinical study support from Miltenyi Biotech. JK received further research support from Novartis and Gadeta.
Consent for publication
All eligible patients provided written informed consent before transplantation. The study was approved by the Medisch Ethische Toetsingscommissie Utrecht (METC Utrecht, METC nr 21-322), in accordance with the Declaration of Helsinki.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Stuut, A., Weverling, F., Janssen, A. et al. Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantation. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-03063-0
Received: 05 June 2026
Revised: 07 September 2026
Accepted: 21 September 2026
Published: 06 October 2026
Version of record: 06 October 2026
DOI: https://doi.org/10.1038/s41409-026-03063-0
来源:Nature 健康护理主题 · nature.com